NASDAQ:ABIO

ARCA biopharma Stock Forecast, Price & News

$3.61

-0.05 (-1.37 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.60

▼

$3.70

50-Day Range

$3.06

▼

$3.90

52-Week Range

$2.92

▼

$8.61

Volume210,560 shs

Average Volume670,388 shs

Market Capitalization$52.02 million

P/E RatioN/A

Dividend YieldN/A

Beta2.75

30 days | 90 days | 365 days | Advanced Chart

Receive ABIO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

About ARCA biopharma

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase 2 clinical trial for the treatment of diseases caused by ribonucleic acid viruses initially focusing on COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase 2 trial for the treatment of atrial fibrillation in patients with chronic heart failure (HF). The company also engages in the development of AB171, a thiol-containing derivative isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

ARCA biopharma, Inc. (NASDAQ:ABIO) Short Interest Down 31.6% in May
June 15, 2021 | americanbankingnews.com

ARCA biopharma, Inc. (NASDAQ:ABIO) Sees Large Increase in Short Interest
June 2, 2021 | americanbankingnews.com

ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 | finance.yahoo.com

Christopher Graybill Joins ARCA as Vice President, Clinical Development
May 5, 2021 | finance.yahoo.com

ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer
May 3, 2021 | finance.yahoo.com

ARCA racing brings diversity and inclusion to Toledo Speedway
April 29, 2021 | msn.com

ARCA driver placed on ventilator after fiery Talladega crash
April 25, 2021 | msn.com

Corey Heim wins Talladega ARCA race marred by fiery wreck
April 24, 2021 | msn.com

ARCA driver Taylor Gray hospitalized, Truck debut on hold
April 8, 2021 | msn.com

ARCA driver Taylor Gray hospitalized; Truck debut in doubt
April 8, 2021 | msn.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABIO
Previous Symbol
CUSIPN/A
CIK907654
Webarcabio.com
Phone720-940-2200
Employees11
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.87 per share
Price / Book0.74

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares14,410,000
Market Cap$52.02 million
Next Earnings Date8/4/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.90 out of 5 stars

Medical Sector

1177th out of 2,100 stocks

Diagnostic Substances Industry

22nd out of 35 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for ARCA biopharma.

2.2 Community Rank

Outperform Votes
ARCA biopharma has received 123 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ARCA biopharma has received 154 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ARCA biopharma has received 55.60% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ARCA biopharma and other stocks. Vote “Outperform” if you believe ABIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ABIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ARCA biopharma does not currently pay a dividend.
Dividend Growth
ARCA biopharma does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ARCA biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $64,200.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.48% of the stock of ARCA biopharma is held by insiders.
Percentage Held by Institutions
Only 6.14% of the stock of ARCA biopharma is held by institutions.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of ARCA biopharma is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ARCA biopharma is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ARCA biopharma has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

ARCA biopharma (NASDAQ:ABIO) Frequently Asked Questions

What stocks does MarketBeat like better than ARCA biopharma?

Wall Street analysts have given ARCA biopharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ARCA biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a decrease in short interest in May. As of May 28th, there was short interest totaling 323,400 shares, a decrease of 31.6% from the May 13th total of 472,700 shares. Based on an average daily trading volume, of 342,500 shares, the days-to-cover ratio is presently 0.9 days. Currently, 2.3% of the shares of the company are short sold.
View ARCA biopharma's Short Interest.

When is ARCA biopharma's next earnings date?

ARCA biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for ARCA biopharma.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) issued its quarterly earnings results on Tuesday, May, 11th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks' consensus estimate of ($1.87) by $1.54.
View ARCA biopharma's earnings history.

How has ARCA biopharma's stock been impacted by COVID-19?

ARCA biopharma's stock was trading at $3.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABIO stock has increased by 7.4% and is now trading at $3.61.
View which stocks have been most impacted by COVID-19.

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the following people:

Dr. Michael R. Bristow, Co-Founder, Pres, CEO & Director (Age 76, Pay $441.61k)
Mr. Thomas A. Keuer, Chief Operating Officer (Age 62, Pay $402.61k)
Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 62, Pay $376.38k)
Mr. C. Jeffrey Dekker, Chief Financial Officer (Age 56)
Dr. Debra Marshall FACC, M.D., Chief Medical Officer

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma CEO Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among ARCA biopharma's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ARCA biopharma's key competitors?

Some companies that are related to ARCA biopharma include Lucira Health (LHDX), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), ImmuCell (ICCC), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), Biomerica (BMRA), Achieve Life Sciences (ACHV), Global WholeHealth Partners (GWHP), StageZero Life Sciences (GNWSF), StageZero Life Sciences (GNWSD), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Fuse Science (DROP).
View all of ABIO's competitors.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

Who are ARCA biopharma's major shareholders?

ARCA biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include GSA Capital Partners LLP (0.65%), Geode Capital Management LLC (0.55%), Morgan Stanley (0.28%), PDT Partners LLC (0.12%) and Virtu Financial LLC (0.12%).
View institutional ownership trends for ARCA biopharma.

Which major investors are selling ARCA biopharma stock?

ABIO stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for ARCA biopharma or view top insider-selling stocks.

Which major investors are buying ARCA biopharma stock?

ABIO stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Geode Capital Management LLC, Morgan Stanley, and PDT Partners LLC.
View insider buying and selling activity for ARCA biopharma or or view top insider-buying stocks.

How do I buy shares of ARCA biopharma?

Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $3.61.

How much money does ARCA biopharma make?

ARCA biopharma has a market capitalization of $52.02 million.

How many employees does ARCA biopharma have?

ARCA biopharma employs 11 workers across the globe.

What is ARCA biopharma's official website?

The official website for ARCA biopharma is arcabio.com.

Where are ARCA biopharma's headquarters?

ARCA biopharma is headquartered at 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at 720-940-2200 or via email at [email protected]

This page was last updated on 6/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here